Genmab A/S
Genmab A/S Fundamental Analysis
Genmab A/S (GNMSF) shows strong financial fundamentals with a PE ratio of 4.73, profit margin of 29.86%, and ROE of 18.99%. The company generates $13.0B in annual revenue with strong year-over-year growth of 30.67%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 89.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze GNMSF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentGNMSF demonstrates superior asset utilization.
Valuation Score
ExcellentGNMSF trades at attractive valuation levels.
Growth Score
ExcellentGNMSF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentGNMSF maintains a strong and stable balance sheet.
Profitability Score
ExcellentGNMSF achieves industry-leading margins.
Key Financial Metrics
Is GNMSF Expensive or Cheap?
P/E Ratio
GNMSF trades at 4.73 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, GNMSF's PEG of -0.10 indicates potential undervaluation.
Price to Book
The market values Genmab A/S at 3.16 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 2.70 times EBITDA. This is generally considered low.
How Well Does GNMSF Make Money?
Net Profit Margin
For every $100 in sales, Genmab A/S keeps $29.86 as profit after all expenses.
Operating Margin
Core operations generate 33.17 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.99 in profit for every $100 of shareholder equity.
ROA
Genmab A/S generates $30.32 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genmab A/S produces operating cash flow of $3.18B, showing steady but balanced cash generation.
Free Cash Flow
Genmab A/S generates strong free cash flow of $2.90B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $47.05 in free cash annually.
FCF Yield
GNMSF converts 15.76% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
4.73
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.10
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.16
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.41
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.95
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.19
vs 25 benchmark
ROA
Return on assets percentage
0.30
vs 25 benchmark
ROCE
Return on capital employed
0.38
vs 25 benchmark
How GNMSF Stacks Against Its Sector Peers
| Metric | GNMSF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 4.73 | 28.23 | Better (Cheaper) |
| ROE | 18.99% | 737.00% | Weak |
| Net Margin | 29.86% | -46175.00% (disorted) | Strong |
| Debt/Equity | 0.95 | 0.35 | Weak (High Leverage) |
| Current Ratio | 2.02 | 4.10 | Strong Liquidity |
| ROA | 30.32% | -17785.00% (disorted) | Strong |
GNMSF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genmab A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
290.79%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
252.79%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
470.91%
Industry Style: Defensive, Growth, Innovation
High Growth